Research graph
References from Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Hallmarks of cancer: the next generation
10.1016/j.cell.2011.02.013 · 2011 · External reference
Innate and adaptive immune cells in the tumor microenvironment
10.1038/ni.2703 · 2013 · External reference
The Immune Microenvironment and Cancer Metastasis
10.1101/cshperspect.a037424 · 2020 · External reference
Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion
10.1126/science.1203486 · 2011 · External reference
New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
10.1016/j.coi.2014.01.004 · 2014 · External reference
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
10.1016/j.coi.2012.12.003 · 2013 · External reference
Immune suppression and reversal of the suppressive tumor microenvironment
10.1093/intimm/dxy042 · 2018 · External reference
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
10.1177/1758835920937612 · 2020 · External reference
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
10.1146/annurev-pathol-042020-042741 · 2021 · External reference
The Basis of Oncoimmunology
10.1016/j.cell.2016.01.049 · 2016 · External reference
The Tumor Microenvironment Innately Modulates Cancer Progression
10.1158/0008-5472.can-18-3962 · 2019 · External reference
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
10.1093/annonc/mdu450 · 2015 · External reference
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
10.1038/s41523-021-00346-1 · 2021 · External reference
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
10.3390/cells10020223 · 2021 · External reference
Differential macrophage programming in the tumor microenvironment
10.1016/j.it.2011.12.001 · 2012 · External reference
Neutralizing tumor-promoting chronic inflammation: a magic bullet?
10.1126/science.1232227 · 2013 · External reference
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
10.1038/bjc.2013.634 · 2013 · External reference
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer
10.1007/s10555-021-09968-0 · 2021 · External reference
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
10.1038/ncomms15081 · 2017 · External reference
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
10.1016/j.cell.2018.05.060 · 2018 · External reference
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
10.1016/j.cell.2019.03.005 · 2019 · External reference
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018 · External reference
Cancer immunoediting and resistance to T cell-based immunotherapy
10.1038/s41571-018-0142-8 · 2019 · External reference
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
10.1084/jem.20051848 · 2006 · External reference
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
10.1016/j.ccr.2012.04.024 · 2012 · External reference
Roles of tumor suppressors in regulating tumor-associated inflammation
10.1038/cdd.2014.131 · 2014 · External reference
Immune modulatory effects of oncogenic KRAS in cancer
10.1038/s41467-020-19288-6 · 2020 · External reference
Biological Functions of the ING Proteins
10.3390/cancers11111817 · 2019 · External reference
Newly identified tumor suppressor functions of ING proteins
10.1016/j.coph.2022.102324 · 2023 · External reference
The emerging role of inhibitor of growth 4 as a tumor suppressor in multiple human cancers
10.1159/000430108 · 2015 · External reference
The essential role of tumor suppressor gene ING4 in various human cancers and non-neoplastic disorders
2019 · External reference
Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer
10.1016/j.humpath.2010.10.012 · 2011 · External reference
Negative regulation of NF-kappaB by the ING4 tumor suppressor in breast cancer
10.1371/journal.pone.0046823 · 2012 · External reference
ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer
10.1016/j.clbc.2020.11.011 · 2021 · External reference
A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis
10.1158/0008-5472.can-10-0425 · 2010 · External reference
The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis
10.1038/nature02329 · 2004 · External reference
The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes
10.1128/mcb.00697-08 · 2008 · External reference
Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1
10.1158/0008-5472.can-10-3040 · 2010 · External reference
Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-kappaB signaling pathway
10.1007/s11033-013-2675-3 · 2013 · External reference
NF-kappaB, inflammation, immunity and cancer: coming of age
10.1038/nri.2017.142 · 2018 · External reference
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
10.1038/nature10983 · 2012 · External reference
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
10.1038/ncomms11479 · 2016 · External reference
PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer
2019 · External reference
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum
10.1101/gad.14.8.994 · 2000 · External reference
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
10.1038/ng747 · 2001 · External reference
WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer
10.1158/0008-5472.can-16-3565 · 2017 · External reference
LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress
10.1016/j.canlet.2014.06.011 · 2014 · External reference
Cxcl10 Chemokine Induces Migration of ING4-Deficient Breast Cancer Cells via a Novel Cross Talk Mechanism between the Cxcr3 and Egfr Receptors
10.1128/mcb.00382-21 · 2022 · External reference
Improved vectors and genome-wide libraries for CRISPR screening
10.1038/nmeth.3047 · 2014 · External reference
Genome-scale CRISPR-Cas9 knockout screening in human cells
10.1126/science.1247005 · 2014 · External reference
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer
10.1080/2162402x.2016.1257452 · 2017 · External reference
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
10.3390/ijms222413311 · 2021 · External reference
Heterogeneity of tumor cells from a single mouse mammary tumor
1978 · External reference
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor
1992 · External reference
Mouse 4T1 breast tumor model
2001 · External reference
Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer
10.1158/0008-5472.can-06-0709 · 2006 · External reference
Pro-tumoral immune cell alterations in wild type and Shb-deficient mice in response to 4T1 breast carcinomas
10.18632/oncotarget.24643 · 2018 · External reference
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
10.3389/fonc.2020.01195 · 2020 · External reference
Comprehensive molecular portraits of human breast tumours
10.1038/nature11412 · 2012 · External reference
Solar Simulated Light Induces Cutaneous Squamous Cell Carcinoma in Inbred Mice: A Clinically Relevant Model to Investigate T-Cell Responses
10.1016/j.jid.2021.06.005 · 2021 · External reference
Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes
10.1111/cas.15751 · 2023 · External reference
Cytotoxic CD4(+) T cells in cancer: Expanding the immune effector toolbox
10.1016/j.immuni.2021.11.015 · 2021 · External reference
Granzyme-Producing CD4 T Cells in Cancer and Autoimmune Disease
10.4049/immunohorizons.2100017 · 2021 · External reference
The Era of Cytotoxic CD4 T Cells
10.3389/fimmu.2022.867189 · 2022 · External reference
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance
10.1016/j.immuni.2007.08.014 · 2007 · External reference
Tumor-associated macrophages: from mechanisms to therapy
10.1016/j.immuni.2014.06.010 · 2014 · External reference
Macrophage polarization in tumour progression
10.1016/j.semcancer.2008.03.004 · 2008 · External reference
The complex role of tumor-infiltrating macrophages
10.1038/s41590-022-01267-2 · 2022 · External reference
Clinical relevance of tumour-associated macrophages
10.1038/s41571-022-00620-6 · 2022 · External reference
Perforin and granzymes: function, dysfunction and human pathology
10.1038/nri3839 · 2015 · External reference
Granzymes in cancer and immunity
10.1038/cdd.2009.206 · 2010 · External reference
CD4 CTL, a Cytotoxic Subset of CD4(+) T Cells, Their Differentiation and Function
10.3389/fimmu.2017.00194 · 2017 · External reference
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
10.1084/jem.20091918 · 2010 · External reference
Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
10.1016/j.cell.2020.05.017 · 2020 · External reference
IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells
10.1016/j.cellimm.2009.03.002 · 2009 · External reference
CRTAM determines the CD4+ cytotoxic T lymphocyte lineage
10.1084/jem.20150519 · 2016 · External reference
CD4(+) Cytotoxic T cells—Phenotype, Function and Transcriptional Networks Controlling Their Differentiation Pathways
10.1016/j.imlet.2022.05.001 · 2022 · External reference
Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling
10.1371/journal.pone.0182786 · 2017 · External reference
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
10.1158/1078-0432.ccr-18-3200 · 2019 · External reference
Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes
2023 · External reference
